We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · August 26, 2020

Pyrotinib + Trastuzumab + AI as First-Line Treatment for HER2+/HR+ Metastatic or Locally Advanced Breast Cancer: Study Protocol

BMC Cancer

 

Additional Info

BMC Cancer
Pyrotinib With Trastuzumab and Aromatase Inhibitors as First-Line Treatment for HER2 Positive and Hormone Receptor Positive Metastatic or Locally Advanced Breast Cancer: Study Protocol of a Randomized Controlled Trial
BMC Cancer 2020 Jul 13;[EPub Ahead of Print], C Wang, Y Lin, Y Zhou, F Mao, H Zhu, J Guan, X Zhang, S Shen, X Huang, C Chen, R Yao, J Zhao, Q Sun

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading